Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer
1. 系统已在2025-07-16 09:49:14对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s00280-014-2505-x
文献链接: http://link.springer.com/10.1007/s00280-014-2505-x
其他信息:
出版社: Springer Science and Business Media LLC
作者: Jun Cao; Jian Zhang; Zhonghua Wang; Biyun Wang; Fangfang Lv; Leiping Wang; Xichun Hu
全文下载地址: http://link.springer.com/content/pdf/10.1007/s00280-014-2505-x.pdf